FDA Expected to Lift Peptide Restrictions: What Traders Need to Know Right Now

The FDA is expected to lift longstanding restrictions on certain peptides, according to a report from The New York Times — and the market is already pricing in the reversal. For traders positioned in biotech, compounding pharmacy plays, or pharmaceutical sector ETFs, this is not a background news item. This is a catalyst.

The expected regulatory shift would reverse a controversial crackdown that began in 2023, when the FDA moved certain peptides — including popular compounds like BPC-157, TB-500, and others used widely in anti-aging and recovery medicine — onto its “bulk drug substances” restricted list. That move hammered compounding pharmacies and sparked immediate legal challenges. Now, with the FDA expected to lift those restrictions, the sector is watching for a clean reversal with significant upside for the right plays.

Why This FDA Ruling Matters Beyond the Headlines

Peptides are short chains of amino acids that function as signaling molecules in the body. Unlike traditional pharmaceuticals, many peptides are difficult to patent, which means they largely flow through compounding pharmacies rather than large pharmaceutical manufacturers. That’s exactly why the FDA’s restriction — and now its expected reversal — matters so profoundly to a specific slice of the market.

When the FDA originally moved to restrict access to these compounds in 2023, the ripple effects were immediate and multidirectional:

• Compounding pharmacies saw compliance costs spike and revenue streams narrow overnight
• Peptide API (active pharmaceutical ingredient) suppliers lost a significant revenue channel
• Telehealth platforms offering peptide-based protocols had to rapidly restructure their product offerings
• Patients and practitioners scrambled for legal alternatives or offshore sources

The reversal would unwind most of that damage. And in markets, reversals of policy restrictions are often more powerful catalysts than the original restriction — because pent-up demand, suppressed capital, and latent revenue all return at once.

The Stocks and Sectors in Play

Identifying the right vehicle for this trade requires understanding where the value chain actually sits. This is not a simple “buy pharma” story. The beneficiaries are nuanced.

Compounding Pharmacy-Adjacent Names

The largest publicly traded compounding pharmacy operator with meaningful peptide exposure is Fagron (traded on Euronext Brussels: FAGR), though pure-play U.S.-listed options are limited. Domestic compounding pharmacy operators are mostly private or embedded within larger specialty pharmacy groups.

However, companies like PharMerica (now part of BrightSpring Health Services, BTSG) and Shields Health Solutions (owned by Walgreens Boots Alliance, WBA) have indirect compounding exposure. WBA in particular has been a troubled name, but a favorable regulatory catalyst in the specialty compounding space could provide temporary relief momentum worth watching on short-dated options.

Telehealth Platforms With Peptide Programs

This is where traders should focus. Telehealth platforms that pivoted away from peptide protocols after the 2023 restriction now have a clear path back to higher-margin services.

• Hims & Hers Health (HIMS): This is arguably the highest-leverage play. HIMS has been one of the most volatile biotech-adjacent names of the past two years, swinging dramatically on GLP-1 compounding rulings. With peptide access expected to return, HIMS’s wellness and recovery protocol revenue could expand meaningfully. The options market on HIMS is liquid and the implied volatility is likely to expand ahead of any official announcement.
• LifeMD (LFMD): Smaller, more volatile, but directly positioned in the telehealth-to-compounding pipeline. A high-risk, high-reward name for aggressive traders.
• Teladoc Health (TDOC): More broadly diversified, so the beta to this specific catalyst is lower — but it’s a liquid name with active options chains if you want exposure with more cushion.

Pharmaceutical Sector ETFs

For traders who prefer sector-level exposure over single-stock risk:

• XBI (SPDR S&P Biotech ETF): The go-to liquid vehicle for broad biotech exposure. Highly responsive to FDA policy shifts. Options are extremely liquid with tight bid/ask spreads.
• IBB (iShares Biotechnology ETF): More large-cap weighted, slightly less volatile than XBI, but still meaningful FDA sensitivity.

How to Structure the Trade: Options Strategies Worth Considering

Before structuring anything, understand the timeline risk. The FDA is expected to lift the restriction — that word carries weight. “Expected” means the announcement has not happened. The NYT is reporting based on sources, and regulatory agencies have reversed course before. Any trade must account for:

1. Announcement timing uncertainty — could be days, could be weeks
2. Scope uncertainty — which specific peptides are included in the lifted restriction
3. Implementation uncertainty — will compounding pharmacies get immediate clearance or a phased re-authorization?

With that in mind, here are three structural approaches sorted by risk tolerance:

Conservative: Long XBI Call Spreads

Buy a call spread on XBI with 30-45 days to expiration. For example:

• Buy the XBI $105 call
• Sell the $115 call
• Net debit: defined, capped risk
• Max profit: if XBI rallies through $115 by expiration

This caps your upside but gives you defined risk in a name that will benefit broadly from any FDA biotech deregulation news, not just the peptide ruling specifically.

Moderate: HIMS Long Calls, 30-60 DTE

HIMS tends to have large implied moves on regulatory news. A long call position 30-60 days out gives you time for the announcement to arrive while participating in IV expansion if sources start leaking more details. Select a strike 5-8% out-of-the-money to balance premium cost against leverage.

Watch the earnings calendar — HIMS’s next earnings report could compound or complicate the position.

Aggressive: LFMD Long Stock or Long Calls

LifeMD is a small-cap name that could see outsized percentage moves if the FDA ruling directly restores its peptide-based revenue programs. Position sizing here must be small — this is a lottery-ticket allocation at most, not a core position.

The Regulatory Backdrop: Why This Reversal Is Happening Now

Context is everything in regulatory trades. The FDA’s original 2023 restriction on peptides came during a period of aggressive agency action on compounding, driven in part by concerns about safety standards and the use of unregulated bulk substances in clinical settings. Critics argued the agency was being overly broad, sweeping well-tolerated and widely used compounds into the same category as genuinely dangerous unregulated substances.

That argument gained legal traction. Several compounding pharmacy groups filed suits challenging the FDA’s authority to categorically restrict bulk substances without individualized safety reviews. Meanwhile, the political environment shifted.

The current administration has made regulatory rollback a stated priority, with an emphasis on reducing what it describes as unnecessary burdens on healthcare access. FDA leadership appointments over the past several months have signaled a more permissive posture toward compounding and alternative modalities. The NYT reporting tracks cleanly with that trajectory.

This is not a surprise reversal out of nowhere. Traders who have been following the compounding pharmacy legal battles and the administration’s deregulatory signaling have seen this coming. What the NYT report provides is confirmation that the expected has moved from likely to imminent.

What the Official Announcement Will Actually Say (And What to Watch For)

When the FDA formally announces the rule change, the devil will be in the details. Here’s what will move markets:

The broader and more immediate the authorization, the larger the upside catalyst for HIMS, LFMD, and compounding-adjacent plays. A narrow or delayed ruling would likely cause a “sell the news” reaction after any pre-announcement run-up.

Internal Context: Related Plays Already on Our Radar

This FDA peptide development connects directly to two other trading themes we’ve been tracking on OptionRaft:

• The GLP-1 Compounding Wars: The ongoing legal battle between compounding pharmacies and branded GLP-1 manufacturers (Novo Nordisk, Eli Lilly) has already demonstrated how rapidly FDA policy shifts can move telehealth stocks. The peptide ruling is a second front in the same broader regulatory war. Traders familiar with how HIMS moved on semaglutide compounding rulings have a clear playbook here.
• Biotech Deregulation Wave: The administration’s broader posture toward FDA has created a favorable environment for biotech trading in 2026. We’ve covered this theme in our analysis of the XBI setup and the impact of faster drug approval timelines on small-cap biotech names.

Timing Your Entry: Pre-Announcement vs. Post-Confirmation

The hardest part of trading catalyst events is entry timing. You face a classic trade-off:

Enter now (pre-announcement):

• Benefit from any further IV expansion as more outlets pick up the NYT story
• Risk holding through any delay or scope-narrowing in the final rule
• Risk that the announcement is already partially priced in

Wait for confirmation (post-announcement):

• Eliminate the uncertainty of “expected” vs. “confirmed”
• Likely miss a significant portion of the move if the ruling is broad and immediate
• Better suited for longer-dated positions in the sustained recovery story

The right answer depends on your risk tolerance and position sizing discipline. For most traders, a partial entry now with a plan to add on confirmation is the balanced approach. Keep initial size small enough that you can hold through a volatile pre-announcement period without emotional decision-making.

For research and screening tools, platforms like TradingView make it straightforward to set price alerts on HIMS, XBI, and LFMD so you can monitor entry points without watching the tape all day.

Conclusion: Regulatory Reversals Are Among the Cleanest Catalysts

The FDA is expected to lift restrictions on certain peptides, and the market will reprice affected names the moment that expectation converts to confirmation. The question for traders is not whether this matters — it clearly does — but how to size, structure, and time the position to extract maximum value with disciplined risk management.

The highest-probability plays are HIMS for single-stock leverage and XBI for sector-level exposure with broader deregulation beta. Watch the scope of the official announcement closely: a broad, immediate restoration of compounding pharmacy access is the bull case; a narrow or delayed ruling is the trap.

Stay close to the headlines. Set your alerts. Size your positions for the uncertainty, not the certainty. And when the FDA makes it official, have your plan ready to execute — not to formulate.